Aignostics is an international, interdisciplinary team powering the next generation of precision medicine and advancing the fields of AI and pathology. Founded in 2018 as a spin-off from Charité Berlin and the Berlin Institute of Health, based on years of research, the company offers a range of products and services geared toward precision medicine from offices in Berlin and New York.

Our mission is to transform drug development and improve patient outcomes with AI that delivers novel insights for precision medicine. We have proprietary access to multimodal data from over 30 million patients at leading university hospitals and laboratories. The team comprises data scientists, machine learning engineers, pathologists, and biologists providing expert input and oversight for all products and services.

The company culture is defined by fairness, honesty, humility, and a mission-driven focus. They embrace diversity, equity, and inclusion, promote open idea meritocracy, teamwork, and prioritize a healthy work-life balance. Aignostics is ISO 13485 and 27001 certified and has a GCP-ready clinical trial platform.